The FDA issued an approvable letter for Glumetza, a once-daily, extended-release version of the diabetes drug metformin, driving up Depomed Inc.'s stock value by 11 percent. (BioWorld Today)

Two serious adverse events - one ending in death - was enough for Biogen Idec Inc. and Elan Corp. plc to suspend marketing of their multiple sclerosis drug, Tysabri, just three months after FDA approval. (BioWorld International)